Current Challenges in Chimeric Antigen Receptor T-cell Therapy in Patients With B-cell Lymphoid Malignancies

다국어 초록 (Multilingual Abstract)

Chimeric antigen receptor (CAR) T-cell therapy is a promising immunotherapy based on genetically engineered T cells derived from patients. The introduction of CAR T-cell therapy has changed the treatment paradigm of patients with B-cell lymphoid malignancies. However, challenging issues including managing life-threatening toxicities related to CAR T-cell infusion and resistance to CAR T-cell therapy, leading to progression or relapse, remain. This review summarizes the issues with currently approved CAR T-cell therapies for patients with relapsed or refractory B-cell lymphoid malignancies, including lymphoma and myeloma. We focus on unique toxicities after CAR T-cell therapy, such as cytokine-related events and hematological toxicities, and the mechanisms underlying post-CAR T-cell failure.

참고문헌 (Reference)

1 Jain MD, "Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma" 137 : 2621-2633, 2021

2 Scholler N, "Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma" 28 : 1872-1882, 2022

3 Locke FL, "Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma" 4 : 4898-4911, 2020

4 Henter JI, "Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation" 100 : 2367-2373, 2002

5 Maude SL, "Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia" 378 : 439-448, 2018

6 Fowler NH, "Tisagenlecleucel in adult relapsed or refractory follicular lymphoma : the phase 2 ELARA trial" 28 : 325-332, 2022

7 Schuster SJ, "Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma" 380 : 45-56, 2019

8 Hirayama AV, "The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells" 133 : 1876-1887, 2019

9 Li Y, "The pathogenesis, diagnosis, prevention, and treatment of CAR-T cell therapy-related adverse reactions" 13 : 950923-, 2022

10 Rejeski K, "The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL" 10 : e004475-, 2022

11 Gattinoni L, "T memory stem cells in health and disease" 23 : 18-27, 2017

12 Lee DW, "T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults : a phase 1 dose-escalation trial" 385 : 517-528, 2015

13 Mehta PH, "T cell fitness and autologous CAR T cell therapy in haematologic malignancy" 12 : 780442-, 2021

14 Nastoupil LJ, "Standard-of-care axicabtagene ciloleucel for relapsed or refractory large Bcell lymphoma : results from the US lymphoma CAR T Consortium" 38 : 3119-3128, 2020

15 Si S, "Spotlight on tocilizumab in the treatment of CAR-Tcell-induced cytokine release syndrome : clinical evidence to date" 16 : 705-714, 2020

16 Wehrli M, "Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome(ICANS)" 10 : e003847-, 2022

17 Schubert ML, "Side-effect management of chimeric antigen receptor(CAR)T-cell therapy" 32 : 34-48, 2021

18 Juluri KR, "Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy" 6 : 2055-2068, 2022

19 Shalabi H, "Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma" 103 : e215-e218, 2018

20 La Rosée P, "Recommendations for the management of hemophagocytic lymphohistiocytosis in adults" 133 : 2465-2477, 2019

21 Byun Ja Min, "Practical issues in CAR T-cell therapy" 58 : S11-S12, 2023

22 Hoffmann MS, "Overcoming barriers to referral for chimeric antigen receptor T cell therapy in patients with relapsed/refractory diffuse large B cell lymphoma" 29 : 440-448, 2023

23 Rejeski K, "Oligoclonal T-cell expansion in a patient with bone marrow failure after CD19 CAR-T therapy for Richter-transformed DLBCL" 140 : 2175-2179, 2022

24 Lemoine J, "Non-relapse mortality after CAR T-cell therapy for large B-cell lymphoma : a LYSA study from the DESCAR-T Registry" 7 : 6589-6598, 2023

25 Norelli M, "Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells" 24 : 739-748, 2018

26 Alvarez-Fernàndez C, "Memory stem T cells modified with a redesigned CD30-chimeric antigen receptor show an enhanced antitumor effect in Hodgkin lymphoma" 10 : e1268-, 2021

27 Neelapu SS, "Managing the toxicities of CAR T-cell therapy" 37 (37): 48-52, 2019

28 Santomasso BD, "Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy : ASCO Guideline" 39 : 3978-3992, 2021

29 Major A, "Management of hemophagocytic lymphohistiocytosis(HLH)associated with chimeric antigen receptor T-cell(CAR-T)therapy using anti-cytokine therapy : an illustrative case and review of the literature" 62 : 1765-1769, 2021

30 Yoo Jae Won, "Management of adverse events in young adults and children with acute B-cell lymphoblastic leukemia receiving anti-CD19 chimeric antigen receptor(CAR)T-cell therapy" 58 : S20-S28, 2023

31 Thompson JA, "Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology" 20 : 387-405, 2022

32 Daver N, "Malignancy-associated haemophagocytic lymphohistiocytosis in adults" 18 : 169-171, 2017

33 Shah NN, "Longterm follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL" 39 : 1650-1659, 2021

34 Park JH, "Longterm follow-up of CD19 CAR therapy in acute lymphoblastic leukemia" 378 : 449-459, 2018

35 Ladbury C, "Long-term follow-up of bridging therapies prior to CAR T-cell therapy for relapsed/refractory large B cell lymphoma" 15 : 1747-, 2023

36 Kamdar M, "Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an openlabel, randomised, phase 3 trial" 399 : 2294-2308, 2022

37 Abramson JS, "Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas(TRANSCEND NHL 001) : a multicentre seamless design study" 396 : 839-852, 2020

38 Wang M, "KTE-X19CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma" 382 : 1331-1342, 2020

39 Shah BD, "KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study" 398 : 491-502, 2021

40 Rainone M, "Interferongamma blockade in CAR T-cell therapy-associated macrophage activation syndrome/hemophagocytic lymphohistiocytosis" 7 : 533-536, 2023

41 Zafar A, "Intensity of cyclophosphamide-based bridging therapy before chimeric antigen receptor T cell therapy in myeloma" 29 : 504-, 2023

42 Bücklein V, "Inferior outcomes of EU versus US patients treated with CD19 CAR-T for relapsed/refractory large B-cell lymphoma : association with differences in tumor burden, systemic inflammation, bridging therapy utilization, and CAR-T product use" 7 : e907-, 2023

43 Nahas GR, "Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy(PCTT)" 61 : 940-943, 2020

44 Nellan A, "Improved CNS exposure to tocilizumab after cerebrospinal fluid compared to intravenous administration in rhesus macaques" 132 : 662-666, 2018

45 Singh N, "Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T-cell dysfunction" 10 : 552-567, 2020

46 Holtzman NG, "Immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma : predictive biomarkers and clinical outcomes" 23 : 112-121, 2021

47 Hines MR, "Immune effector cell-associated hemophagocytic lymphohistiocytosislike syndrome" 29 : 438-, 2023

48 Rejeski K, "Immune effector cell-associated hematotoxicity : EHA/EBMT consensus grading and best practice recommendations" 142 : 865-877, 2023

49 Munshi NC, "Idecabtagene vicleucel in relapsed and refractory multiple myeloma" 384 : 705-716, 2021

50 Jain T, "How I treat cytopenias after CAR T-cell therapy" 141 : 2460-2469, 2023

51 Hines MR, "Hemophagocytic lymphohistiocytosis-like toxicity(carHLH)after CD19-specific CAR T-cell therapy" 194 : 701-707, 2021

52 Rosado FGN, "Hemophagocytic lymphohistiocytosis : an update on diagnosis and pathogenesis" 139 : 713-727, 2013

53 Henter JI, "HLH-2004 : diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis" 48 : 124-131, 2007

54 Bethge WA, "GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany" 140 : 349-358, 2022

55 Galli E, "G-CSF does not worsen toxicities and efficacy of CAR-T cells in refractory/relapsed B-cell lymphoma" 55 : 2347-2349, 2020

56 Dekker L, "Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia" 6 : 1969-1976, 2022

57 Aldoss I, "Favorable activity and safety profile of memory-enriched CD19-targeted chimeric antigen receptor T-cell therapy in adults with high-risk relapsed/refractory ALL" 29 : 742-753, 2023

58 Le RQ, "FDA approval summary : tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome" 23 : 943-947, 2018

59 Zhang C, "Engineering CAR-T cells" 5 : 22-, 2017

60 Gust J, "Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells" 7 : 1404-1419, 2017

61 Roddie C, "Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma" 7 : 2872-2883, 2023

62 Liévin R, "Effect of early granulocyte-colony-stimulating factor administration in the prevention of febrile neutropenia and impact on toxicity and efficacy of anti-CD19 CAR-T in patients with relapsed/refractory B-cell lymphoma" 57 : 431-439, 2022

63 Fried S, "Early and late hematologic toxicity following CD19 CAR-T cells" 54 : 1643-1650, 2019

64 Topp MS, "Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma" 195 : 388-398, 2021

65 Jackson HJ, "Driving CAR T-cells forward" 13 : 370-383, 2016

66 Sandler RD, "Diagnosis and management of secondary HLH/MAS following HSCT and CAR-T cell therapy in adults; a review of the literature and a survey of practice within EBMT centres on behalf of the autoimmune diseases working party(ADWP)and transplant complications working party(TCWP)" 11 : 524-, 2020

67 Gust J, "Cytokines in CAR T cellassociated neurotoxicity" 11 : 577027-, 2020

68 Freyer CW, "Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies" 146 : 940-948, 2020

69 Riegler LL, "Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy" 15 : 323-335, 2019

70 Santomasso BD, "Clinical and biological correlates of neurotoxicity associated with CAR Tcell therapy in patients with B-cell acute lymphoblastic leukemia" 8 : 958-971, 2018

71 Berdeja JG, "Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study" 398 : 314-324, 2021

72 Grupp SA, "Chimeric antigen receptor-modified T cells for acute lymphoid leukemia" 368 : 1509-1518, 2013

73 Sommermeyer D, "Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo" 30 : 492-500, 2016

74 Ramos CA, "Chimeric antigen receptor(CAR)-engineered lymphocytes for cancer therapy" 11 : 855-873, 2011

75 Neelapu SS, "Chimeric antigen receptor T-cell therapy — assessment and management of toxicities" 15 : 47-62, 2018

76 Deng Q, "Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas" 26 : 1878-1887, 2020

77 Harris CE, "COVID-19and other viral infections in patients with hematologic malignancies" 43 : e390778-, 2023

78 Plaks V, "CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel" 138 : 1081-1085, 2021

79 Rejeski K, "CARHEMATOTOX : a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma" 138 : 2499-2513, 2021

80 Myers RM, "Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL" 40 : 932-944, 2022

81 Bivona Giulia ; Agnello Luisa ; Ciaccio Marcello, "Biomarkers for prognosis and treatment response in COVID-19 patients" 41 : 540-548, 2021

82 Jacobson CA, "Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial" 23 : 91-103, 2022

83 Locke FL, "Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma" 386 : 640-654, 2022

84 Neelapu SS, "Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma" 377 : 2531-2544, 2017

85 Lee DW, "ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells" 25 : 625-638, 2019

86 Gattinoni L, "A human memory T cell subset with stem cell-like properties" 17 : 1290-1297, 2011

87 Yoon SE, "A comprehensive analysis of adult patients with secondary hemophagocytic lymphohistiocytosis : a prospective cohort study" 99 : 2095-2104, 2020